Glutamate activates the MAPK pathway by inhibiting LPAR1 expression and promotes anlotinib resistance in thyroid cancer.

Liu B, Peng Y, Su Y, Diao C, Cha L, Cheng R

Open source

DOI
10.1007/s12672-025-02853-0
Published
2025 Jun 13
Container
Discover oncology
Publisher
Not recorded
Open access
yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1007/s12672-025-02853-0,
  title = {Glutamate activates the MAPK pathway by inhibiting LPAR1 expression and promotes anlotinib resistance in thyroid cancer.},
  author = {Liu B and Peng Y and Su Y and Diao C and Cha L and Cheng R},
  year = {2025},
  journal = {Discover oncology},
  doi = {10.1007/s12672-025-02853-0},
  url = {https://doi.org/10.1007/s12672-025-02853-0}
}

RIS

TY  - JOUR
TI  - Glutamate activates the MAPK pathway by inhibiting LPAR1 expression and promotes anlotinib resistance in thyroid cancer.
AU  - Liu B
AU  - Peng Y
AU  - Su Y
AU  - Diao C
AU  - Cha L
AU  - Cheng R
PY  - 2025
JO  - Discover oncology
DO  - 10.1007/s12672-025-02853-0
UR  - https://doi.org/10.1007/s12672-025-02853-0
ER  - 

APA

B, L., Y, P., Y, S., C, D., L, C., & R, C. (2025). Glutamate activates the MAPK pathway by inhibiting LPAR1 expression and promotes anlotinib resistance in thyroid cancer.. Discover oncology. https://doi.org/10.1007/s12672-025-02853-0

Source records